The phase III, randomized, multicenter commodore 2 trial: results from the study of crovalimab vs eculizumab in paroxysmal nocturnal hemoglobinuria (PNH) patients naive to complement inhibitors

被引：0

作者：

Roeth, A. ^{[1
]}

He, G. ^{[2
]}

Brodsky, A. ^{[3
]}

Chai-Adisaksopha, C. ^{[4
]}

Dumagay, T. ^{[5
]}

Demichelis Gomez, R. ^{[6
]}

Hoglund, M. ^{[7
]}

Kelly, R. J. ^{[8
]}

Lee, J. -H ^{[9
]}

Nishimura, J. -, I ^{[10
]}

Obara, N. ^{[11
]}

Risitano, A. ^{[12
]}

Gaya, A. ^{[13
]}

Appius, A. ^{[14
]}

Gentile, B. ^{[15
]}

Negricea, R. ^{[16
]}

Zhang, Z. ^{[17
]}

Buatois, S. ^{[14
]}

Han, B. ^{[18
]}

机构：

[1] Univ Duisburg Essen, Univ Hosp Essen, Dept Hematol & Stem Cell Transplantat, West German Canc Ctr, Essen, Germany

[2] Jiangsu Prov Hosp, Nanjing, Peoples R China

[3] Univ Buenos Aires, Div Hematol, Hosp Clin Jose de San Martin, Buenos Aires, DF, Argentina

[4] Chiang Mai Univ, Fac Med, Chiang Mai, Thailand

[5] Univ Philippines, Philippine Gen Hosp, Div Hematol, Dept Med, Manila, Philippines

[6] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Dept Hematol, Mexico City, DF, Mexico

[7] Uppsala Univ, Dept Med Sci, Uppsala, Sweden

[8] St James Univ Hosp, Dept Haematol, Leeds, W Yorkshire, England

[9] Univ Ulsan, Dept Internal Med, Coll Med, Asan Med Ctr, Seoul, South Korea

[10] Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, Osaka, Japan

[11] Univ Tsukuba Hosp, Dept Hematol, Ibaraki, Japan

[12] AORN San Giuseppe Moscati, Hematol & BMT Unit, Avellino, Italy

[13] Hosp Clin Barcelona, Hematol Dept, Barcelona, Spain

[14] F Hoffmann La Roche Ltd, Basel, Switzerland

[15] Genentech Inc, San Francisco, CA USA

[16] Roche Prod Ltd, Welwyn Garden City, Basel, England

[17] Roche Prod Dev, Shanghai, Peoples R China

[18] Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1056

引用

页码：294 / 295

页数：2

共 50 条

[1] The phase III randomized, multicenter commodore 1 trial: comparison of crovalimab vs eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria (PNH)
Roeth, A.
Scheinberg, P.
Villa Cle, D.
Edwards, J.
Giai, V.
Hus, M.
Kim, J. S.
Barrenetxea Lekue, C.
Nagy, Z.
Nur, E.
Panse, J.
Ueda, Y.
Yenerel, M. N.
Appius, A.
Balachandran, N.
Chebon, S.
Gentile, B.
Buatois, S.
Kulasekararaj, A.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 200 - 201
[2] Biomarker Analyses in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab and Eculizumab: Results from the Phase III Randomized COMMODORE 2 Trial
Lundberg, Pontus
de la Iglesia, Silvia
Kelly, Richard J.
Kulasekararaj, Austin
Nishimura, Jun-Ichi
Risitano, Antonio M.
Roeth, Alexander
Buatois, Simon
Chebon, Sammy
Patel, Himika
Kiialainen, Anna
[J]. BLOOD, 2023, 142
[3] Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition
Roeth, Alexander
He, Guangsheng
Tong, Hongyan
Lin, Zenghua
Wang, Xiaoqin
Chai-Adisaksopha, Chatree
Lee, Je-Hwan
Brodsky, Andres
Hantaweepant, Chattree
Dumagay, Teresita E.
Demichelis-Gomez, Roberta
Rojnuckarin, Ponlapat
Sun, Jing
Hoeglund, Martin
Jang, Jun Ho
Gaya, Anna
Silva, Fernando
Obara, Naoshi
Kelly, Richard J.
Beveridge, Leigh
Buatois, Simon
Chebon, Sammy
Gentile, Brittany
Lundberg, Pontus
Sreckovic, Sasha
Nishimura, Jun-ichi
Risitano, Antonio
Han, Bing
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (09) : 1768 - 1777
[4] Safety of Crovalimab Versus Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Pooled Results from the Phase III COMMODORE 1, COMMODORE 2, and COMMODORE 3 Studies
Roeth, Alexander
Fu, Rong
He, Guangsheng
Alzahrani, Hazza A.
Chou, Sheng-Chieh
Hicheri, Yosr
Kazmierczak, Maciej
Recova, Viviane Lacorte
Uchiyama, Michihiro
Vladareanu, Ana Maria
Beveridge, Leigh
Buatois, Simon
Buri, Muriel
Shi, Dayu
Balachandran, Nadiesh
Srekovic, Sasha
Scheinberg, Phillip
[J]. BLOOD, 2023, 142
[5] Patient-Reported Outcomes (PROs) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab and Eculizumab: Results from the Phase III Randomized COMMODORE 2 and COMMODORE 1 Trials
Panse, Jens
Cermak, Jaroslav
Kyselova, Olena
Gotoh, Akihiko
Sahin, Fahri
Schrezenmeier, Hubert
Chang, Alice C.
Gentile, Brittany
Uguen, Marianne
Han, Bing
[J]. BLOOD, 2023, 142
[6] Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria
Scheinberg, Phillip
Cle, Diego Villa
Kim, Jin Seok
Nur, Erfan
Yenerel, Mustafa N.
Barcellini, Wilma
Bonito, Debora
Giai, Valentina
Hus, Marek
Lee, Yoojin
Lekue, Cristina Barrenetxea
Panse, Jens
Ueda, Yasutaka
Buatois, Simon
Gentile, Brittany
Kiialainen, Anna
Patel, Himika
Sreckovic, Sasha
Uguen, Marianne
Edwards, John
Nagy, Zsolt
Kulasekararaj, Austin G.
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (09) : 1757 - 1767
[7] Trial in Progress: The Phase III, Randomized, Open-Label, Multicenter COMMODORE 2 Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria Not Previously Treated with Complement Inhibitors
Kulasekararaj, Austin
He, Guangsheng
Munir, Talha
Pu, Jeffrey
Risitano, Antonio
Roth, Alexander
Sima, Camelia S.
Appius, Anita
Sostelly, Alexandre
Sreckovic, Sasha
Vignal, Charlotte
Nishimura, Jun-Ichi
[J]. BLOOD, 2020, 136
[8] Trial in Progress: The Phase III, Randomized, Open-Label, Multicenter COMMODORE 1 Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Complement Inhibitors
Risitano, Antonio
Roth, Alexander
Kulasekararaj, Austin
Pu, Jeffrey
Nishimura, Jun-Ichi
Wright, Lilyan
Appius, Anita
Sostelly, Alexandre
Sreckovic, Sasha
Vignal, Charlotte
Munir, Talha
[J]. BLOOD, 2020, 136
[9] Two Currently Recruiting Randomized Phase III Trials: COMMODORE 1 and 2 Evaluating Crovalimab Vs Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria with or without Current Anti-Complement Therapy
Kulasekararaj, Austin G.
Risitano, Antonio
Roeth, Alexander
He, Guangsheng
Pu, Jeffrey
Wright, Lilyan
Appius, Anita
Sostelly, Alexandre
Sreckovic, Sasha
Stanzel, Sven F.
Munir, Talha
Nishimura, Jun-Ichi
[J]. BLOOD, 2021, 138
[10] Results from the First Phase 3 Crovalimab (C5 Inhibitor) Study (COMMODORE 3): Efficacy and Safety in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Liu, Hui
Xia, Linghui
Weng, Jianyu
Zhang, Fengkui
He, Chuan
Gao, Sujun
Jia, Jinsong
Chang, Alice C.
Lundberg, Pontus
Sima, Camelia S.
Shi, Jane
Xiao, Zhenyu
Zhang, Yuchen
Zhang, Zilu
Fu, Rong
[J]. BLOOD, 2022, 140

← 1 2 3 4 5 →